Pernix Therapeutics Holdings, Inc. (“Pernix” or the “Company”) (NASDAQ: PTX), a specialty pharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2013.
“Pernix exited 2013 with accelerating momentum -- revenue exceeded guidance, product price increases were implemented, and expense reductions began in earnest,” said Doug Drysdale, Chairman and Chief Executive Officer. “February 2014 delivered additional good news as fresh product acquisition capital was paired with proven management to create a strong pharma platform for shareholders.”
Help employers find you! Check out all the jobs and post your resume.
